Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (19788)	4/29/1998 1:04:00 AM
From: SnowShredder	Respond to of 32384

Scott, (Melanoma) Sorry to hear about your friend. I believe that Somatix has an Ex vivo cancer immunotherapy in phase II... Genopoietic has a In vivo HSVtk/Glancyclovir product in phase I/II... and Viagene has an In vivo cancer immunotherapy in phase I. I don't know how any of these trials are going, but I hope this helps. Best of luck, Where'd He Go?

To: Scott H. Davis who wrote (19788)	4/29/1998 4:59:00 AM
From: Andreas Helke	Respond to of 32384

Off Topic to Scott Angiogenesis inhibitors should help even against melanonma. Entremeds (ENMD) endostatin works very well against melanoma in a mouse model. (T. Boehm et. al. - Nature, vol 390 27. november 1997, page 404-407) But this protein is still far away from human clinical trials. Sugen (SUGN) has an small molecule angiogenesis inhibitor in a phase I clinical trial, but I don't think that they are testing melanoma. If you check the Entremed thread in november you might find some more companies working on angiogenesis inhibitors. techstocks.com Andreas